Artelo Biosciences, INC

Artelo Biosciences held its Annual Meeting of Stockholders on July 17, 2026, where key proposals including director elections and an increase in authorized shares were approved.

Artelo Biosciences, Inc. has entered into an At The Market Offering Agreement to sell up to $6.53 million of its common stock through H.C. Wainwright & Co., LLC.

Artelo Biosciences has successfully met Nasdaq's minimum stockholders' equity and annual meeting requirements, ending a period of potential delisting risk.

Artelo Biosciences announced a $300,000 financing deal and a strategic expansion of its ART27.13 program to address muscle loss in GLP-1 therapy patients, supported by preclinical data and a new patent filing.

Artelo Biosciences, a clinical-stage biopharmaceutical company, reported a significant increase in net loss and a net capital deficiency for 2025, raising substantial doubt about its ability to continue as a going concern.

Artelo Biosciences will implement a 1-for-3 reverse stock split to enhance marketability and liquidity, effective March 10, 2026.

Artelo Biosciences filed its Q2 2026 Form 10-Q, detailing ongoing R&D efforts and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Artelo Biosciences reported increased net losses and a going concern warning for Q3 2025, despite positive interim clinical trial results for ART27.13 and ART26.12, and successful capital raises.

Artelo Biosciences reported a widened net loss in Q2 2025, alongside significant capital raises and a new strategy to invest heavily in Solana (SOL) cryptocurrency.

Artelo Biosciences announces its Q1 2025 results, highlighting clinical trial progress alongside concerns about its ability to continue as a going concern due to ongoing losses and the need for additional funding.

Artelo Biosciences reports a net loss of $1.132 million for the three months ended September 30, 2024, and provides an update on its clinical programs and financial position.

Artelo Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $4.9 million for the six months ended June 30, 2024, while advancing its clinical programs.

Artelo Biosciences reported promising interim clinical trial results for its drug candidates but faces substantial doubt about its ability to continue as a going concern and a Nasdaq delisting threat due to insufficient stockholders' equity.

Artelo Biosciences details its capital stock structure, potential risks, and future outlook in its annual 10-K filing, highlighting its focus on lipid-signaling modulation and clinical-stage biopharmaceutical development.

Artelo Biosciences' 10-K filing outlines the company's capital structure, including common stock, preferred stock, and warrants, along with regulatory compliance and risk factors.

Connie Matsui, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Douglas Blayney, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Gregory Reyes, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Robert Martin Emanuele, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Steven Kelly, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Tamara A Favorito, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Artelo Biosciences schedules its 2026 Annual Meeting for July 17, 2026, to elect directors and seek approval to triple authorized common stock.

Artelo Biosciences, Inc. has supplemented its proxy statement to include a new proposal for stockholder approval: the ratification of MaloneBailey LLP as its independent auditor for the fiscal year ending December 31, 2026, at its adjourned virtual Annual Meeting on January 30, 2026.

Artelo Biosciences announces its 2025 Annual Meeting to elect directors and vote on executive compensation, following a year of continued net losses and declining shareholder returns.

Artelo Biosciences, Inc. calls a special stockholder meeting to approve a significant increase in authorized common and preferred stock to address Nasdaq non-compliance and facilitate future capital raises.

Artelo Biosciences, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Artelo Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on December 20, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Artelo Biosciences, Inc. has filed a Form S-1 registration statement to allow for the resale of up to 9,820,294 shares of common stock by certain selling stockholders.

Artelo Biosciences files an S-1 registration statement for the resale of up to 4.27 million common shares by Square Gate Capital, potentially accessing up to $50 million in future equity financing.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is conducting a best-efforts public offering to raise up to $10.9 million while addressing Nasdaq listing compliance issues and reporting positive interim clinical trial data.

Artelo Biosciences files an S-1/A for a best efforts public offering of up to 1.64M shares and warrants to raise capital and address a Nasdaq listing deficiency.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is offering up to 1.64 million shares and pre-funded warrants to raise capital, primarily for working capital and to address Nasdaq listing deficiencies.

Artelo Biosciences filed an S-1 registration statement for the resale of up to 899,972 shares by securityholders, highlighting both promising clinical trial results and significant financial challenges, including a going concern doubt.

Daniel S. Farb has reduced his beneficial ownership in Artelo BioSciences, Inc. to 0.8% after selling common stock on October 20 and 21, 2025.

Artelo Biosciences and Daniel Farb's affiliates enter a standstill agreement, resolving director nominations and setting voting commitments.

Daniel S. Farb has updated his beneficial ownership in Artelo Biosciences, Inc. to 7.7% following a recent underwritten public offering.

Activist investor Daniel S. Farb, holding a 9.8% stake in Artelo Biosciences, has nominated himself and Scott D. Pomfret to the company's Board of Directors, citing undervaluation and a desire to unlock shareholder value.

Armistice Capital, LLC and Steven Boyd have reported a 0.0% beneficial ownership of Artelo Biosciences, Inc. common stock, indicating a full divestment.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported a combined beneficial ownership of 4.8% in Artelo Biosciences, Inc. common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Artelo Biosciences, Inc. common stock as of March 31, 2026.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have disclosed a beneficial ownership stake of 9.99% in Artelo Biosciences, Inc.